Lilly launches first of its kind trial for RET fusion-positive NSCLC
Selpercatinib was designed to inhibit native RET signaling as well as anticipated acquired resistance mechanisms
Read More
Tag: LOXO-292
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
